{"id":"ramosetron-ondansetron-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperglycemia (dexamethasone-related)"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1643895","moleculeType":"Small molecule","molecularWeight":"279.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ramosetron and ondansetron are selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonists that block serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract, preventing chemotherapy-induced and postoperative nausea and vomiting. Dexamethasone, a glucocorticoid, potentiates this effect through anti-inflammatory mechanisms and modulation of neurotransmitter pathways involved in emesis. The combination provides synergistic antiemetic coverage across multiple pathways.","oneSentence":"This is a combination of three antiemetic agents: ramosetron and ondansetron block 5-HT3 receptors to prevent nausea/vomiting, while dexamethasone is a corticosteroid that reduces inflammation and enhances antiemetic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:48.874Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":"Postoperative Nausea and Vomiting","enrollment":27034},{"nctId":"NCT03061396","phase":"NA","title":"The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints","status":"UNKNOWN","sponsor":"Tianjin University of Traditional Chinese Medicine","startDate":"2017-02-17","conditions":"Electro-acupuncture, Chemotherapy-induced Nausea and Vomiting","enrollment":208},{"nctId":"NCT02803788","phase":"PHASE4","title":"Post-operative Nausea Vomiting in Laparoscopic Cholecystectomy","status":"UNKNOWN","sponsor":"Government Medical College, Haldwani","startDate":"2015-07","conditions":"Postoperative Nausea and Vomiting","enrollment":100},{"nctId":"NCT01536691","phase":"PHASE3","title":"Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2011-06","conditions":"Cancer, Malignancy","enrollment":338}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["anti-emetics"],"phase":"marketed","status":"active","brandName":"ramosetron, ondansetron, dexamethasone","genericName":"ramosetron, ondansetron, dexamethasone","companyName":"Government Medical College, Haldwani","companyId":"government-medical-college-haldwani","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of three antiemetic agents: ramosetron and ondansetron block 5-HT3 receptors to prevent nausea/vomiting, while dexamethasone is a corticosteroid that reduces inflammation and enhances antiemetic effects. Used for Chemotherapy-induced nausea and vomiting (CINV), Postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}